Commodore Capital LP Acquires Shares of 1,823,196 Alto Neuroscience, Inc. $ANRO

Commodore Capital LP purchased a new stake in shares of Alto Neuroscience, Inc. (NYSE:ANRO) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,823,196 shares of the company’s stock, valued at approximately $32,453,000. Alto Neuroscience accounts for about 2.2% of Commodore Capital LP’s portfolio, making the stock its 21st biggest holding. Commodore Capital LP owned about 5.87% of Alto Neuroscience at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Peapod Lane Capital LLC increased its stake in Alto Neuroscience by 1.1% in the third quarter. Peapod Lane Capital LLC now owns 281,963 shares of the company’s stock valued at $1,136,000 after purchasing an additional 3,106 shares in the last quarter. Torren Management LLC bought a new stake in shares of Alto Neuroscience in the 4th quarter valued at $62,000. AlphaCore Capital LLC raised its stake in Alto Neuroscience by 100.0% during the 4th quarter. AlphaCore Capital LLC now owns 20,000 shares of the company’s stock worth $356,000 after buying an additional 10,000 shares during the period. Balyasny Asset Management L.P. acquired a new stake in Alto Neuroscience during the 4th quarter worth $198,000. Finally, Armistice Capital LLC lifted its holdings in Alto Neuroscience by 0.7% during the third quarter. Armistice Capital LLC now owns 1,636,000 shares of the company’s stock worth $6,577,000 after acquiring an additional 12,000 shares in the last quarter.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on ANRO shares. Bank of America began coverage on Alto Neuroscience in a report on Tuesday, May 5th. They issued a “buy” rating and a $35.00 price target for the company. Jefferies Financial Group reiterated a “buy” rating and issued a $35.00 price objective on shares of Alto Neuroscience in a research report on Monday, March 16th. Weiss Ratings upgraded shares of Alto Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, May 1st. Wedbush upped their price target on shares of Alto Neuroscience from $21.00 to $24.00 and gave the company a “neutral” rating in a report on Thursday, May 14th. Finally, JonesTrading dropped their price objective on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating on the stock in a report on Thursday, April 2nd. Eight investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $35.25.

Alto Neuroscience Price Performance

Shares of ANRO opened at $21.87 on Thursday. The company has a quick ratio of 20.52, a current ratio of 20.52 and a debt-to-equity ratio of 0.07. Alto Neuroscience, Inc. has a twelve month low of $2.15 and a twelve month high of $28.44. The stock has a market capitalization of $767.49 million, a P/E ratio of -9.04 and a beta of 1.22. The company has a 50 day moving average of $22.68 and a 200-day moving average of $19.72.

Alto Neuroscience (NYSE:ANRO) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.24). As a group, equities research analysts forecast that Alto Neuroscience, Inc. will post -3.01 EPS for the current fiscal year.

Alto Neuroscience Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.